Medline ® Abstract for Reference 27
Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Smith CC, Shah NP
Clin Cancer Res. 2011 Nov;17(21):6605-7. Epub 2011 Oct 25.
Patients with chronic phase chronic myeloid leukemia who respond to imatinib have a rapid initial decrease in BCR-ABL transcript levels (α), followed by a slow decline (β). The rate ofβdecrease is consistent with declining leukemic stem cells and may predict which patients may safely discontinue therapy.
Division of Hematology-Oncology, Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA.